Inflammatory breast cancer is not a common type of breast cancer. Overall, it accounts for about 2% to 5% of all cases of breast cancer. Inflammatory breast cancer develops and progresses rapidly, which accounts for a poor prognosis. The median survival for patients with inflammatory breast cancer is 15 months, even with treatment. It presents with signs and symptoms of inflammation, and is often mistaken for cellulitis. Physical exam may reveal a warm, indurated and erythematous breast, without an underlying mass, but axillary adenopathy is common. Also, it may present as a reddened breast, without systemic features of inflammation. Prompt biopsy followed by treatment by an interprofessional team is highly recommended. Unlike other breast cancers, initial treatment of inflammatory breast cancer is chemotherapy, followed by surgery and radiation.
The goal of this inflammatory breast cancer continuing education program is to provide pharmacists, physicians and imaging technologists with information about inflammatory breast cancer, its pathophysiology, presentation and treatment. After studying the information presented here, you will be able to:
- Describe the pathology, presentation and examination of patients with inflammatory breast cancer
- Discuss the role of chemotherapy, surgery and radiation in patients with primary inflammatory breast cancer, including management of adverse effects
- List the novel types of treatment for patients with advanced inflammatory breast cancer
- Discuss the types of cancer drugs used to treat inflammatory breast cancer
- List other non-drug therapies for treatment of inflammatory breast cancer
This course is intended for an interprofessional audience, including pharmacists, physicians and imaging technologists.
Pharmacists: Take this version of the course to ensure you receive appropriate credit.
This activity is approved for Category A continuing education credit by the American Society of Radiologic Technologists (ASRT) for 09/02/2015 to 10/01/2018.
This activity may be available in multiple formats or from different sponsors. ARRT regulations state that an individual may not repeat a self-learning activity for credit if it was reported in the same or any subsequent biennium.
Course Originally Released on:
Date of Most Recent Review:
Course Termination/Update Date:
Unless stated above, the planners and authors of this course have declared no relevant conflicts of interest that relate to this educational activity. OnCourse Learning guarantees this educational activity is free from bias.
Please see CE Course Instructions to learn how to earn CE credit for this module.